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OBJECTIVE — Both gestational diabetes mellitus (GDM) and mild glucose intolerance in
pregnancyidentifywomenatincreasedriskoffuturetype2diabetes.Inthiscontext,wequeried
whether metabolic changes that occur in the 1st year postpartum vary in relation to gestational
glucose tolerance status.
RESEARCH DESIGN AND METHODS — Three-hundred-and-ninety-two women un-
derwent glucose challenge test (GCT) and oral glucose tolerance test (OGTT) in pregnancy
followed by repeat OGTT at both 3 months’ postpartum and 12 months’ postpartum. The
antepartum testing deﬁned four gestational glucose tolerance groups: GDM (n  107); gesta-
tional impaired glucose tolerance (GIGT) (n  75); abnormal GCT with normal glucose toler-
ance (NGT) on OGTT (abnormal GCT NGT) (n  137); and normal GCT with NGT on OGTT
(normal GCT NGT) (n  73).
RESULTS — The prevalence of dysglycemia progressively increased across the groups from
normalGCTNGTtoabnormalGCTNGTtoGIGTtoGDMatboth3months’postpartum(2.7%
to10.2%to18.7%to34.6%,P0.0001)and12months’postpartum(2.7%to11.7%to17.3%
to 32.7%, P  0.0001). Between 3 and 12 months’ postpartum, the groups did not differ with
respect to changes in waist circumference, weight, or insulin sensitivity. Importantly, however,
they exhibited markedly different changes in -cell function (Insulin Secretion-Sensitivity In-
dex-2 [ISSI-2]) (P  0.0036), with ISSI-2 declining in both the GDM and GIGT groups. Fur-
thermore, on multiple linear regression analysis, both GDM (t  3.06, P  0.0024) and GIGT
(t  2.18, P  0.03) emerged as independent negative predictors of the change in ISSI-2
between 3 and 12 months’ postpartum.
CONCLUSIONS — Women with GDM and GIGT exhibit declining -cell function in the
1st year postpartum that likely contributes to their future diabetic risk.
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T
he diagnosis of gestational diabetes
mellitus (GDM) identiﬁes a popula-
tion of young women who are at
highriskofdevelopingtype2diabeteson
the order of 20–60% in the ﬁrst 5 years
following an index pregnancy (1–3). A
systematic review of studies evaluating
the risk of progression to type 2 diabetes
followingGDMhasdemonstratedthatthe
cumulative incidence of diabetes in-
creases markedly in the ﬁrst 5 years’ post-
partum and appears to plateau after 10
years (3). Thus, events in the early post-
partum years are likely to be important
indeterminingdiabeticriskinthispatient
population. At present, however, little is
known about the pathophysiologic
changes that take place in these early
years following a pregnancy complicated
by GDM.
A recent series of reports have dem-
onstratedthatevenwomenwithmildglu-
cose intolerance in pregnancy (i.e., less
severe than GDM) have an increased risk
ofultimatelydevelopingpre-diabetesand
diabetes(4–9).Themagnitudeofthisrisk
isproportionaltothedegreeofgestational
dysglycemia, with the highest risk in
women with GDM and proportionately
lower risk in women with milder abnor-
malities of gestational glucose tolerance
(4). It thus emerges that the spectrum of
abnormal glucose homeostasis in preg-
nancy identiﬁes a continuum of risk for
future diabetes and, based on the tempo-
ral ﬁndings pertaining to GDM, patho-
physiologic changes that occur in the
earlypostpartumyearsmayberelevantto
the manifestation of this risk potential.
Therefore, in the current study, our ob-
jectivewastoperformalongitudinaleval-
uation of the metabolic changes that take
placeinthe1styearpostpartuminawell-
characterizedcohortofwomenrepresent-
ing the full spectrum of glucose tolerance
in pregnancy and hence a broad range of
future diabetic risk.
RESEARCH DESIGN AND
METHODS— This analysis was con-
ducted in the context of an ongoing ob-
servational study of early events in the
naturalhistoryoftype2diabetesinwhich
acohortofwomenrecruitedatthetimeof
antepartum GDM screening is under-
going longitudinal metabolic character-
ization in pregnancy and at 3 months’
postpartum, 12 months’ postpartum, and
every 2 years thereafter for 10 years.
The study protocol has previously been
described in detail (4,5,8,10). Standard
obstetrical practice at our institution in-
volves universal screening for GDM in all
pregnant women at 24–28 weeks’ gesta-
tion by a glucose challenge test (GCT),
followed by referral for a diagnostic oral
glucose tolerance test (OGTT) if the GCT
resultisabnormal(deﬁnedasplasmaglu-
cose 7.8 mmol/l at 1 h following the
ingestionof50gofglucose).Inthisstudy,
regardless of the GCT result, all partici-
pants underwent a 3-h 100-g OGTT for
determination of glucose tolerance status
in pregnancy. Recruitment was per-
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priortotheOGTT.Itshouldbenotedthat
the recruitment of women following an
abnormalGCTwasdesignedtoenrichthe
studypopulationforwomenwithvarying
degrees of antepartum glucose intoler-
ance(4,10).At3months’postpartumand
1 year postpartum, participants returned
for reassessment including evaluation of
glucosetoleranceby2-h75-gOGTT.The
study protocol was approved by the
Mount Sinai Hospital Research Ethics
Board, and all participants provided writ-
ten informed consent. The study presents
data on the ﬁrst 392 women that have
completed their 12-month postpartum
visit as of March 2009, as part of this 10-
year prospective observational cohort
study.
Gestational glucose tolerance status
The GCT and 3-h 100-g OGTT in preg-
nancy stratiﬁed participants into the fol-
lowing four gestational glucose tolerance
groups: GDM (deﬁned as 2 glucose val-
ues above the National Diabetes Data
Group [NDDG] diagnostic criteria on the
OGTT[11]);gestationalimpairedglucose
tolerance (GIGT) (deﬁned as only 1 glu-
cosevalueaboveNDDGthresholds);nor-
mal glucose tolerance (NGT) on the
antepartumOGTTwithanabnormalpre-
ceding GCT (abnormal GCT NGT); and
normal glucose tolerance on the OGTT
with a normal preceding GCT (normal
GCT NGT).
Postpartum study visits
Participantsreturnedtotheclinicalinves-
tigation unit for a 2-h 75-g OGTT at both
3 and 12 months’ postpartum. At both
visits, interviewer-administered ques-
tionnaires were completed, and physical
examinations were performed. No spe-
ciﬁc clinical advice was systematically
provided in this observational study. The
OGTT characterized postpartum glucose
tolerance at both visits into one of the fol-
lowing ﬁve categories per Canadian Dia-
betes Association clinical practice
guidelines (12): diabetes, impaired glu-
cose tolerance (IGT), impaired fasting
glucose (IFG), combined IFG/IGT, and
normal glucose tolerance. Pre-diabetes
refers to IGT, IFG, and combined IFG/
IGT (12).
Laboratory measurements and
physiologic indexes
All OGTTs were performed in the morn-
ing with venous blood samples drawn for
the measurement of glucose and speciﬁc
insulin at fasting and at 30, 60, and 120
minfollowingtheingestionoftheglucose
load as previously described (4,5).
Insulin sensitivity was measured us-
ing the Matsuda index (ISOGTT), a well-
established measure of whole-body
insulin sensitivity that has been validated
against the euglycemic-hyperinsulinemic
clamp (13). ISOGTT is deﬁned as
10,000/ [(FPG  FPI)  (G  I)],
where FPG  fasting plasma glucose,
FPI  fasting plasma insulin, G  mean
glucose during the OGTT, and I  mean
insulin (13). As a secondary measure of
insulin sensitivity (largely hepatic), we
also calculated the reciprocal of the ho-
meostasis model assessment of insulin re-
sistance (1/HOMA-IR). HOMA-IR (14)
was calculated as FPG  FPI/22.5.
The primary measure of -cell func-
tion was the Insulin Secretion-Sensitivity
Index-2 (ISSI-2), an OGTT-derived mea-
sure that is analogous to the disposition
index obtained from the frequently sam-
pled intravenous glucose tolerance test
(15,16). ISSI-2 is deﬁned as the product
of 1) insulin secretion measured by the
ratiooftheareaundertheinsulincurveto
the area under the glucose curve and 2)
insulin sensitivity measured by ISOGTT
(15,16). As a secondary measure of -cell
function, we also calculated the insulino-
genic index (IGI) divided by HOMA-IR
(IGI/HOMA-IR).IGIwascalculatedasthe
ratio of the incremental change in insulin
duringtheﬁrst30minoftheOGTTtothe
incremental change in glucose over the
same time period (17). ISSI-2 exhibits
stronger correlation with the disposition
index than does IGI/HOMA-IR (16) and
thus was used as the primary measure of
-cell function in this study.
Statistical analyses
All analyses were conducted using SAS
(version 9.1; SAS Institute, Cary, NC).
Continuous variables were tested for nor-
mality of distribution, and natural log
transformations of skewed variables were
used, where necessary, in subsequent
analyses.Univariatedifferencesacrossthe
four gestational glucose tolerance groups
were assessed at 3 months’ postpartum
and at 12 months’ postpartum using the
Wilcoxon rank sum test for continuous
variables and the 
2 test for categorical
variables (Table 1). The changes within
each study group between 3 and 12
months’ postpartum in waist circumfer-
ence, weight, insulin sensitivity, and
-cell function, respectively, were com-
paredbetweengroups(Fig.1andsupple-
mental Fig. 2, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc10-0315/DC1). Since
the magnitude of change of these pa-
rameters within each group will be lim-
ited by their respective baseline values at
3months’postpartum(whichdifferedbe-
tween the groups), these comparisons
were adjusted for the baseline values.
Multiple linear regression analyses of the
change in -cell function between 3 and
12 months’ postpartum (dependent vari-
able)wereperformedtoidentifyindepen-
dent predictors of this change with -cell
functionmeasuredbyeitherISSI-2(Table
2) or IGI/HOMA-IR. Covariates in these
models included age, ethnicity, family
history of diabetes, breastfeeding, base-
line -cell function at 3 months’ postpar-
tum, waist circumference, change in
weight between 3 and 12 months’ post-
partum, and gestational glucose tolerance
status.
RESULTS
Characteristics of study population
at baseline and follow-up
Table 1 shows the characteristics of the
study population at baseline (3 months’
postpartum) and at follow-up (12
months’ postpartum) stratiﬁed into the
following four groups based on glucose
tolerance status in pregnancy: normal
GCT NGT (n  73), abnormal GCT NGT
(n137),GIGT(n75),andGDM(n
107). At 3 months’ postpartum, there
were no signiﬁcant differences between
the groups with respect to age, ethnicity,
smoking, breastfeeding, and blood pres-
sure. Although BMI did not differ be-
tween the groups, waist circumference
increased with worsening gestational glu-
cose tolerance (P  0.0337). As antici-
pated, both insulin sensitivity (ISOGTT
and 1/HOMA-IR) and -cell function
(ISSI-2 and IGI/HOMA-IR) progressively
decreased from the normal GCT NGT
group to the abnormal GCT NGT group
toGIGTtoGDMat3months’postpartum
(all P  0.0005). Furthermore, these dif-
ferences translated into a stepwise in-
crease in the prevalence of dysglycemic
states across these four groups (P 
0.0001) (Table 1).
These differences between the groups
persisted at 12 months’ postpartum (Ta-
ble 1). Speciﬁcally, the earlier differences
in waist circumference (P  0.0162), in-
sulin sensitivity (ISOGTT P  0.0001;
1/HOMA-IR P  0.0134), and -cell
function (ISSI-2 P  0.0001; IGI/
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1799Table 1—Clinical, demographic, and metabolic characteristics of study population (n  392) at 3 months’ and 12 months’ postpartum,
stratiﬁed by glucose tolerance status in pregnancy
Normal GCT Abnormal GCT
NGT NGT GIGT GDM P
n 73 137 75 107
At 3 months’ postpartum
Age (years) 35.6 32.7–39.1	 34.8 32.2–37.5	 35.4 33.3–38.5	 35.2 32.3–38.2	 0.5725
Ethnicity 0.2091
White (%) 82.2 81.0 74.7 74.8
Asian (%) 5.5 9.5 16.0 8.4
Other (%) 12.3 9.5 9.3 16.8
Family history of diabetes (%) 39.7 48.5 49.3 61.7 0.0294
Current smoking (%) 5.5 3.7 8.0 3.7 0.5005
Current breastfeeding (%) 94.5 92.0 88.0 97.2 0.0961
BMI (kg/m
2) 25.1 22.6–28.5	 25.0 23.1–28.9	 26.1 23.3–30.1	 26.7 23.5–30.7	 0.2400
Waist circumference (cm) 88.0 80.0–95.0	 85.4 80.0–92.0	 88.0 83.0–97.0	 89.4 81.0–99.0	 0.0337
Systolic BP (mmHg) 108 101–113	 108 101–114	 108 103–115	 111 105–118	 0.0539
Diastolic BP (mmHg) 66 60–70	 64 59–70	 63 60–70	 66 60–72	 0.3293
Insulin sensitivity
ISOGTT 13.4 9.2–17.4	 12.2 8.4–16.9	 8.6 5.9–12.9	 9.0 5.7–13.1	 0.0001
1/HOMA-IR 1.4 1.0–1.9	 1.3 0.8–1.8	 1.1 0.6–1.6	 1.0 0.6–1.6	 0.0005
-Cell function
ISSI-2 1,123 850–1,371	 1,003 815–1,212	 868 733–1,148	 834 628–1,062	 0.0001
IGI/HOMA-IR 13.8 7.9–20.0	 10.1 7.0–16.2	 8.4 5.2–12.8	 8.0 4.4–13.2	 0.0001
OGTT
Fasting glucose (mmol/l) 4.4 4.1–4.6	 4.4 4.2–4.7	 4.7 4.3–5.0	 4.7 4.3–5.0	 0.0001
2-h glucose (mmol/l) 5.7 4.8–6.1	 5.9 5.0–6.9	 6.3 5.2–7.3	 6.7 5.5–8.5	 0.0001
Glucose tolerance status
NGT (%) 97.3 89.8 81.3 65.4 0.0001
Isolated IFG (%) 0 0 1.3 0.9
Isolated IGT (%) 1.4 10.2 10.7 28.0
Combined IFG and IGT (%) 1.4 0 1.3 0
Diabetes (%) 0 0 5.3 5.6
At 12 months’ postpartum
Current smoking (%) 5.5 6.7 9.5 3.7 0.4586
Current breastfeeding (%) 95.9 89.8 88.0 88.8 0.3364
BMI (kg/m
2) 24.2 21.5–27.8	 24.5 21.9–27.9	 25.0 22.5–28.8	 26.4 22.5–30.5	 0.1478
Waist circumference (cm) 82.6 76.5–90.0	 84.0 77.2–91.0	 85.5 80.0–95.0	 87.8 80.0–96.0	 0.0162
Systolic BP (mmHg) 109 100–115	 109 102–117	 110 101–118	 110 103–119	 0.4896
Diastolic BP (mmHg) 64 59–70	 65 59–70	 64 60–70	 66 60–71	 0.2260
Insulin sensitivity
ISOGTT 12.3 8.5–16.8	 10.4 7.1–14.9	 7.7 4.9–13.6	 7.6 4.8–11.1	 0.0001
1/HOMA-IR 1.1 0.6–1.7	 1.0 0.6–1.6	 0.9 0.5–1.5	 0.8 0.5–1.4	 0.0134
-Cell function
ISSI-2 1,055 866–1,433	 977 763–1,238	 842 706–1,053	 787 599–1,047	 0.0001
IGI/HOMA-IR 14.1 9.4–22.8	 10.6 6.3–16.1	 7.2 4.3–11.8	 7.2 4.5–11.3	 0.0001
OGTT
Fasting glucose (mmol/l) 4.5 4.4–4.7	 4.6 4.4–5.0	 4.8 4.5–5.1	 4.8 4.5–5.2	 0.0001
2-h glucose (mmol/l) 5.4 4.7–6.0	 5.8 5.0–7.0	 6.0 5.1–7.1	 6.9 5.6–8.3	 0.0001
Glucose tolerance status
NGT (%) 97.3 88.3 82.7 67.3 0.0002
Isolated IFG (%) 0 0.7 1.3 0
Isolated IGT (%) 2.8 10.2 13.3 29.0
Combined IFG and IGT (%) 0 0 0 0.9
Diabetes (%) 0 0.7 2.7 2.8
Continuous variables are presented as median followed by interquartile range in parentheses and categorical variables are presented as percentages. P values
refer to overall differences across groups as determined by Wilcoxon rank sum test for continuous variables or 
2 test for categorical variables. BP, blood
pressure.
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Similarly, the earlier stepwise increase in
the prevalence of dysglycemic states from
thenormalGCTNGTgrouptotheabnor-
mal GCT NGT group to GIGT to GDM
also persisted at 12 months’ postpartum
(P  0.0002).
Metabolic changes between 3 and 12
months postpartum
In light of their differential future risk of
diabetes, we next sought to determine
whether the gestational glucose tolerance
groups differed with respect to metabolic
changesthattookplacebetween3and12
months’ postpartum. In this regard, it
should ﬁrst be noted that, although the
prevalence of dysglycemia (pre-diabetes
ordiabetes)differedsigniﬁcantlybetween
the groups at both 3 months’ (P 
0.0001)and12months’postpartum(P
0.0001),therateswithineachgroupwere
very similar on both occasions (normal
GCT NGT 2.7% at 3 months and 2.7% at
12months;abnormalGCTNGT10.2and
11.7;GIGT18.7and17.3;andGDM34.6
and 32.7) (supplemental Fig. 1). Thus, in
the absence of ﬂuctuation in the preva-
lenceofdysglycemia,wequeriedwhether
the groups exhibited differential changes
over this 9-month period in physiologic
factors affecting glucose homeostasis in-
cluding obesity, insulin sensitivity, and
-cell function. As shown in Fig. 1A, the
baseline-adjustedchangeinwaistcircum-
ference between 3 and 12 months’ post-
partum was not signiﬁcantly different
between the four gestational glucose tol-
erance groups (P  0.3441). The base-
line-adjusted change in weight suggested
possiblylesserweightlossinwomenwith
GDM compared with their peers, but this
comparison across the groups did not
reach statistical signiﬁcance (P  0.0582)
(Fig. 1B). Importantly, the baseline-
adjusted change in insulin sensitivity
(ISOGTT) also did not differ between the
groups(P0.2852)(Fig.1C).Thisresult
was unchanged with insulin sensitivity
measured by 1/HOMA-IR (P  0.3928)
(supplemental Fig. 2A). In contrast,
however, the groups differed markedly
with respect to their respective changes
in -cell function between 3 and 12
months’ postpartum. Indeed, whereas
women with normal GCT NGT showed
an increase in baseline-adjusted ISSI-2
and those with abnormal GCT NGT
showed little change, both the GIGT
and GDM groups showed a decline in
baseline-adjusted ISSI-2 between 3 and
12 months’ postpartum (P  0.0036)
Figure 1—Baseline-adjusted changes in waist circumference (A), weight (B), insulin sensi-
tivity (C), and -cell function (D) between 3 months’ and 12 months’ postpartum by gesta-
tional glucose tolerance group. To account for the fact that the magnitude of change of these
parameters within each group will be limited by their respective baseline values at 3 months’
postpartum (which differed between the groups), these comparisons are adjusted for the
baseline values.
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an overall 2.6% decline in ISSI-2 in the
GIGT group and a 4.0% decline in ISSI-2
in the GDM group. Furthermore, mea-
surement of -cell function by IGI/
HOMA-IR revealed the same pattern of
differential changes between the groups
with GIGT and GDM again both show-
ing a fall in this measure between 3 and
12 months’ postpartum (P  0.0036)
(supplemental Fig. 2B).
Multiple linear regression analyses
Having shown that the pattern of change
in -cell function varies according to ges-
tational glucose tolerance group, we next
performed multiple linear regression
analyses to determine if other factors may
account for this relationship. Indeed, on
this analysis (Table 2, Model I), both
GDM ( 176.99, t  3.47, P 
0.0006) and GIGT ( 118.83, t 
2.16, P  0.031) emerged as negative
independentpredictorsofthe(dependent
variable) change in ISSI-2 between 3 and
12 months’ postpartum after adjustment
for age, ethnicity, family history of diabe-
tes, breastfeeding, and baseline ISSI-2, in
amodelthatreconciled32.3%ofthevari-
ance in the dependent variable. These in-
dependent associations of GDM (
173.07, t  3.39, P  0.0008) and
GIGT ( 117.54, t  2.14, P 
0.033) persisted after further adjustment
forwaistcircumferenceat3months’post-
partum(Table2,ModelII).Moreover,ad-
ditional adjustment for weight change
between 3 and 12 months’ postpartum
(whichdifferencenearlyachievedstatisti-
cal signiﬁcance) also did not attenuate
theserelationships(GDM[155.67,
t  3.06, P  0.0024]; GIGT [
118.79, t  2.18, P  0.030]) (Table
2, Model III). The same results were ob-
servedwithadjustmentforBMIinmodels
II and III rather than waist circumference
(data not shown). Inclusion of prepreg-
nancy weight also did not change the
ﬁndings (data not shown). In addition,
repeating all of the models using the
change in IGI/HOMA-IR between 3 and
12 months’ postpartum as the dependent
variable also supported these ﬁndings
with both GDM and GIGT consistently
emergingasindependentnegativepredic-
tors of the change in -cell function (data
not shown).
Finally, we also repeated the models
from Table 2 in only those women with
NGT at 3 months’ postpartum. This lim-
ited dataset (n  325) consisted of 71
women in the normal GCT NGT group,
123 in the abnormal GCT NGT group, 61
with GIGT, and 70 women with GDM.
After adjustment for age, ethnicity, family
history of diabetes, breastfeeding, and
baseline ISSI-2 (Model I), GDM remained
a negative independent predictor of the
change in ISSI-2 between 3 and 12
months’ postpartum ( 148.39, t 
2.58, P  0.0103), while GIGT no
longer reached statistical signiﬁcance
( 98.93, t  1.63, P  0.1048).
These results were unchanged after fur-
ther adjustment 1) for waist circumfer-
ence(ModelII)(GDM[141.99,t
2.47,P0.0142];GIGT[97.89,
t1.61,P0.1092])and2)addition-
ally for weight change between 3 and 12
months’ postpartum (Model III) (GDM
[ 124.39, t  2.15, P  0.032];
GIGT [ 96.47, t  1.59, P 
0.1121]). Thus, even when limited to
those women with NGT at 3 months’
postpartum, GDM remained an inde-
pendent predictor of declining -cell
function between 3 and 12 months’
postpartum.
CONCLUSIONS — Women with
GDMhaveachronicdefectin-cellfunc-
tion (18). Although this defect likely an-
tedates the pregnancy (19), it is ﬁrst
detected clinically in the form of insufﬁ-
cient -cell compensation for the severe
acquired insulin resistance of late preg-
nancy resulting in the gestational hyper-
glycemia by which GDM is diagnosed.
While the gestational hyperglycemia typ-
ically resolves following delivery, it is im-
portant to recognize that the -cell defect
inwomenwithGDMisstillpresentinthe
postpartum. Indeed, several studies have
conﬁrmed the presence of chronic -cell
dysfunction (and chronic insulin resis-
tance [19]) in this patient population
many years after the index pregnancy
(4,18–21). Furthermore, it has recently
been demonstrated that GIGT and even
abnormalGCTNGTarebothalsocharac-
terized by -cell dysfunction (of propor-
tionately lesser severity than that of
GDM), and this dysfunction also persists
into the postpartum (4,5,8). Accordingly,
the concept has emerged that the spec-
trum of abnormal glucose homeostasis in
pregnancy identiﬁes a gradient of chronic
-cell dysfunction that may antedate the
pregnancy and translates into a contin-
uum of future risk for the development of
type 2 diabetes, with GDM representing
the most extreme element followed, in
turn, by GIGT (4). In this context, we
sought to determine whether there are
metabolicchangesinthe1styearpostpar-
tum that vary in relation to gestational
glucose tolerance status and, hence, may
be relevant to this gradient of future dia-
betic risk.
Fourkeypointsarisefromthecurrent
study. First, the longitudinal design (with
two assessments in the 1st year postdeliv-
ery) reveals that deterioration of -cell
function is a very early event in women
with GDM and GIGT, taking place within
the1styearpostpartum.Second,theeval-
uation of women across the full spectrum
of antepartum glucose tolerance shows
that the degree of this decline in -cell
function varies in relation to the severity
Table 2—Multiple linear regression analyses of the relationships between gestational glucose
tolerancestatusand(dependentvariable)thechangein-cellfunction(ISSI-2)between3and
12 months’ postpartum
 SEM tP Model r
2
Model I* 32.3%
Abnormal GCT NGT 61.71 47.12 1.31 0.191
GIGT 118.83 55.00 2.16 0.031
GDM 176.99 50.94 3.47 0.0006
Model II** 32.7%
Abnormal GCT NGT 63.58 47.14 1.35 0.178
GIGT 117.54 55.03 2.14 0.033
GDM 173.07 50.99 3.39 0.0008
Model III*** 34.1%
Abnormal GCT NGT 54.52 46.80 1.16 0.245
GIGT 118.79 54.51 2.18 0.030
GDM 155.67 50.87 3.06 0.0024
*Covariates in Model I: age, ethnicity, family history of diabetes, breastfeeding status, -cell function at 3
months’ postpartum, and gestational glucose tolerance group. **Covariates in Model II: covariates in Model
I 
 waist circumference at 3 months’ postpartum. ***Covariates in Model III: covariates in Model II 

change in weight between 3 months’ and 12 months’ postpartum.
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the decline is greatest in women with
GDM followed by those with GIGT,
whereas -cell function does not appear
to worsen in women with NGT in preg-
nancy. Third, this gradient of change in
-cell function in relation to gestational
glucose tolerance status occurs in the ab-
sence of differential changes between the
groups in waist circumference, weight,
and insulin sensitivity, respectively (Fig.
1). Last, these data suggest that the dete-
rioration in -cell function in women
with GDM and GIGT appears to precede
the worsening of glycemia that must oc-
cur for progression to type 2 diabetes.
Speciﬁcally, -cell function declined in
women with GDM and GIGT despite sta-
bleratesofdysglycemiabetween3and12
months’ postpartum (the rates actually
decreased slightly in both groups over
this period) (supplemental Fig. 1), and
GDMremainedanindependentpredictor
of declining -cell function even when
the multiple linear regression analyses
were limited to only those women with
NGT at 3 months’ postpartum. Indeed,
this observation is consistent with a re-
centreportshowingimpaired-cellfunc-
tion at median 7 years’ postpartum in 52
women with previous GDM compared
with39controlwomenwithnormoglyce-
mia in pregnancy despite similar insulin
sensitivity and the maintenance of NGT
(22). Taken together with the current
ﬁndings, these data suggest that chronic
progressive -cell dysfunction is likely
the dominant pathophysiologic defect
driving the progression to type 2 diabetes
in women with a history of GDM. This
idea is further supported by evidence
linking the early preservation of -cell
function in response to thiazolidinedione
therapy with protection from the devel-
opment of diabetes in women with a his-
tory of GDM (23).
In clinical studies, -cell dysfunction
has consistently emerged as an indepen-
dent predictor of incident type 2 diabetes
in several populations (17) including
women with previous GDM (24). In this
context, the model arising from the cur-
rent data is one where the previously
demonstrated gradient of -cell dysfunc-
tion associated with gestational dysglyce-
mia (4) is mirrored by a gradient of
chronic progressive deterioration of
-cell function over time that will ulti-
mately lead to the manifestation of long-
term diabetic risk. In other words, as the
mostextremeelement,womenwithGDM
have the most severe -cell defect at the
outset, coupled with the greatest deterio-
ration over the 1st year postpartum, result-
ing in the highest risk for the development
of diabetes. Furthermore, the demonstra-
tion of this deterioration within the 1st year
postpartum suggests that gestational dys-
glycemia provides the unique opportunity
toidentifyapatientpopulationinwhichthe
early evolution of -cell dysfunction is un-
foldingpriortothedevelopmentofdiabetes
or even pre-diabetes. It follows from these
data that lifestyle modiﬁcation (previously
shown to reduce the risk of type 2 diabetes
in women with a remote history of GDM
[25]) potentially should be instituted as
early as possible in the postpartum to pro-
tect -cell function, although further study
is required.
A limitation of this study is the use of
surrogate measures of insulin sensitivity
and -cell function. However, clamp
studieswouldbedifﬁculttoimplementin
a study of this size (n  392) given their
cost, invasiveness, and time require-
ments. These issues may be particularly
problematic for performing two measure-
ments in the 1st year postpartum in new
mothers,adesignfeaturethatwasintegral
to the novel demonstration of early dete-
rioration of -cell function. Furthermore,
we have used two established and vali-
dated measures for both insulin sensitiv-
ity and -cell function (13–17) with
consistentresultsobservedineachcase.A
second limitation is that causality cannot
beconclusivelyestablishedinanobserva-
tional cohort study owing to the possibil-
ity of unrecognized confounding
(although the biologic plausibility and
consistency of the current data are en-
couraging). There is likely to be pheno-
typic and genetic variability within the
population that will inﬂuence the natural
history of -cell function in the postpar-
tum. The third limitation is that the cur-
rent study does not provide estimates for
theoverallpopulationprevalenceofpost-
partum pre-diabetes/diabetes due to the
nature of the recruitment strategy, which
was designed to enrich the study popula-
tion for varying degrees of antepartum
glucose intolerance. The ﬁnal study limi-
tation is that the current data cannot de-
termine whether similar mechanisms are
responsible for chronic -cell dysfunc-
tion and the increased risk of postpar-
tum metabolic syndrome in women
with glucose intolerance in pregnancy
(10), though it is likely that insulin resis-
tance is relevant to both of these out-
comes.
In summary, the pattern of change in
-cellfunctioninthe1styearpostpartum
varies in relation to glucose tolerance sta-
tus in pregnancy unlike changes in waist
circumference,weight,andinsulinsensitiv-
ity. Indeed, both GDM and GIGT indepen-
dently predict declining -cell function
between 3 and 12 months’ postpartum. It
thus emerges that -cell dysfunction
progresses in the early postpartum in
women with a history of gestational dysgly-
cemiaandislikelyapathophysiologicfactor
contributing to the development of type 2
diabetes in this at-risk patient population.
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